Category Pharma/Biotech

Pint Pharma is pleased to announce that ORLADEYO® (berotralstat) has been approved by the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru for daily oral use in the…

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or “Company”), a clinical-stage biotechnology firm pioneering targeted virotherapies, has confirmed that its Board of Directors has sanctioned a reverse stock split of…

Neuranics, a Glasgow-based deep tech startup, celebrates winning the Deep Tech Investment of the Year award at the UK Angel Investment Awards. The ceremony took place at the Science Museum…

The “Worldwide Market for Clinical Laboratory Services, 9th Edition” has been newly listed on ResearchAndMarkets.com. Gain insights into demographic and disease trends, new developments, company performance, mergers and acquisitions, and…

HAYA Therapeutics, SA, a company specializing in RNA-guided precision medicines focused on long non-coding RNAs (lncRNAs), has announced that its Co-Founders, Samir Ounzain and Daniel Blessing, have been awarded the…

Genmab A/S (Nasdaq: GMAB) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting conditional marketing authorization for epcoritamab (TEPKINLY®). This…

Last year, Brenus Pharma was chosen to join CDL Cancer, a global mentoring program supporting highly scalable, science-driven companies advancing cancer treatments. Distinguished by its innovative STC platform focused on…

Augustine Therapeutics, a pioneering biotech firm dedicated to innovative therapies for neurodegenerative and cardiometabolic diseases, has successfully secured EUR 17 million (USD 18.5 million) in the initial closing of its…

Xeno Biosciences Inc., a company focused on advancing therapies for obesity and metabolic diseases, has initiated a Phase 1b clinical study to evaluate the efficacy, safety, and tolerability of its…

Takeda (TSE:4502/NYSE) unveiled encouraging findings from its Phase 2b study, which evaluated mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare bleeding disorder caused by…

OrsoBio, Inc., a clinical-stage biopharmaceutical company focused on treatments for obesity and associated disorders, has unveiled new data for its liver-targeted mitochondrial protonophore, TLC-6740, at the 84th Scientific Sessions of…